Evidence map›Paper›PMID 25788182›Full record

ArticleHepatology international2015

Analysis of adult 20-year survivors after liver transplantation.

C Dopazo, I Bilbao, L L Castells, G Sapisochin, C Moreiras, I Campos-Varela, J Echeverri, M Caralt, J L Lázaro, R Charco

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Hepatology international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06636409 (Long-term Mortality Post Liver Transplantation in the Era of Modern Immunosuppression.), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06636409 active not recruitingnot on this mapstarted 2023, after this paper: background citation

Long-term Mortality Post Liver Transplantation in the Era of Modern Immunosuppression.

TypeobservationalSponsorUniversity Hospital, MontpellierRan2023 to 2028Enrolled1,343ConditionsLiver TransplantArmsCollection of medical data
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Follow-up of liver transplant recipients.Best practice & research. Clinical gastroenterology
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

C DopazoDepartment of HBP Surgery and Transplants, Hospital Universitario Vall d´Hebron, Universidad Autónoma de Barcelona, Paseo Vall d´Hebron 119-129, 08035, Barcelona, Spain, cdopazo@vhebron.net.
I Bilbao
L L Castells
G Sapisochin
C Moreiras
I Campos-Varela
J Echeverri
M Caralt
J L Lázaro
R Charco
Universitat Autònoma de Barcelona · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiver transplantation (LT) is the treatment of choice for chronic and acute liver failure; however, the status of long-term survivors and allograft function is not well known.

aimTo evaluate the clinical outcome and allograft function of survivors 20 years post-LT, cause of death during the same period and risk factors of mortality.

methodsA retrospective study was conducted from prospective, longitudinal data collected at a single center of adult LT recipients surviving 20 years. A comparative sub-analysis was made with patients who were not alive 20 years post-transplantation to identify the causes of death and risk factors of mortality.

resultsBetween 1988 and 1994, 132 patients received 151 deceased-donors LT and 28 (21%) survived more than 20 years. Regarding liver function in this group, medians of AST, ALT and total bilirubin at 20 years post-LT were 33 IU/L (13-135 IU/L), 27 (11-152 IU/L) and 0.6 mg/dL (0.3-1.1 mg/dL). Renal dysfunction was observed in 40% of patients and median eGFR among 20-year survivors was 64 mL/min/1.73 m(2) (6-144 mL/min/1.73 m(2)). Sixty-one percent of 20-year survivors had arterial hypertension, 43% dyslipidemia, 25% de novo tumors and 21% diabetes mellitus. Infections were the main cause of death during the 1st year post-transplant (32%) and between the 1st and 5th year post-transplant (25%). After 5th year from transplant, hepatitis C recurrence (22%) became the first cause of death. Factors having an impact on long-term patient survival were HCC indication (p = 0.049), pre-transplant renal dysfunction (p = 0.043) and long warm ischemia time (p = 0.016); furthermore, post-transplant factors were diabetes mellitus (p = 0.001) and liver dysfunction (p = 0.05) at 1 year.

conclusionOur results showed the effect of immunosuppression used during decades on long-term outcome in our LT patients in terms of morbidity (arterial hypertension, diabetes mellitus, dyslipidemia and renal dysfunction) and mortality (infections and hepatitis C recurrence).

Indexed as

AdolescentAdultAgedAge FactorsCause of DeathDiabetes MellitusDyslipidemiasFemaleHepatitis CHumansHypertensionImmunosuppression TherapyLiver Function TestsLiver TransplantationMaleMiddle Aged

Identifiers

PMID25788182
PMCPMC4473278
OpenAlexW1970059414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.